Hamburg releases FDA five-year priorities

Share this article:
FDA commissioner Margaret Hamburg says the agency's priorities for the next five years will be advancing regulatory science and innovation, strengthening the global supply chain safety and integrity, strengthening compliance and enforcement activities to support public health, addressing unmet medical needs of special populations, and advancing medical countermeasures and emergency preparedness.
In an all-hands e-mail, Hamburg says the document “will guide our policies and focus our efforts as we respond to the unprecedented public health challenges of the 21st century.”
For drugs, it sets these goals:
  • Conduct postmarket surveillance to ensure early detection of new safety signals;
  • Conduct rigorous studies to understand new drug safety signals and effectively manage emerging risks;
  • Ensure patient and health professional awareness of drug risks and parameters for safe use; and
  • Oversee drug promotion and marketing to ensure that marketed drug labeling and advertising are truthful and not deemed misleading.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?